Yuxian HE Ph.D., Professor

Tel: 86-10-67870275
Email: yhe@ipbcams.ac.cn

Research interests:
  • Molecular mechanism of HIV infection and host immune responses.
  • Development of antiviral neutralizing antibodies, vaccines and therapeutics.

  • Selected publications:
    • Chong H, Qiu Z, Su Y, He Y: The N-Terminal T-T Motif of a Third-Generation HIV-1 Fusion Inhibitor Is Not Required for Binding Affinity and Antiviral Activity. J Med Chem 2015, 58(16):6378-6388.
    • Qiu Z, Chong H, Yao X, Su Y, Cui S, He Y: Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target. AIDS 2015, 29(9):1015-1024.
    • Su Y, Chong H, Qiu Z, Xiong S, He Y: Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket. J Virol 2015, 89(11):5801-5811.
    • Chong H, Qiu Z, Su Y, Yang L, He Y: Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket. AIDS 2015, 29(1):13-21.
    • Chong H, Yao X, Qiu Z, Sun J, Qiao Y, Zhang M, Wang M, Cui S, He Y: The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance. J Antimicrob Chemother 2014, 69(10):2759-2769.
    • Chong H, Qiu Z, Sun J, Qiao Y, Li X, He Y: Two M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK. Retrovirology 2014, 11:40.
    • Wu R, Li X, Leung HC, Cao Z, Qiu Z, Zhou Y, Zheng BJ, He Y: A novel neutralizing antibody against diverse clades of H5N1 influenza virus and its mutants capable of airborne transmission. Antiviral Res 2014, 106:13-23.
    • Wan C, Sun J, Chen W, Yuan X, Chong H, Prabakaran P, Dimitrov DS, He Y: Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity. PLoS One 2013, 8(6):e66638.
    • Chong H, Yao X, Qiu Z, Sun J, Zhang M, Waltersperger S, Wang M, Liu SL, Cui S, He Y: Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1. FASEB J 2013, 27(3):1203-1213.
    • He Y: Synthesized Peptide Inhibitors of HIV-1 gp41-dependent Membrane Fusion. Curr Pharm Des 2013, 19(10):1800-1809.
    • Chong H, Yao X, Sun J, Qiu Z, Zhang M, Waltersperger S, Wang M, Cui S, He Y: The M-T hook structure is critical for design of HIV-1 fusion inhibitors. J Biol Chem 2012, 287(41):34558-34568.
    • Yao X, Chong H, Zhang C, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, He Y, Cui S: Structural Basis of Potent and Broad HIV-1 Fusion Inhibitor CP32M. J Biol Chem 2012, 287(32):26618-26629.
    • Cao Z, Meng J, Li X, Wu R, Huang Y, He Y: The epitope and neutralization mechanism of AVFluIgG01, a broad-reactive human monoclonal antibody against H5N1 influenza virus. PLoS One 2012, 7(5):e38126.
    • Chong H, Yao X, Qiu Z, Qin B, Han R, Waltersperger S, Wang M, Cui S, He Y: Discovery of critical residues for viral entry and inhibition through structural Insight of HIV-1 fusion inhibitor CP621-652. J Biol Chem 2012, 287(24):20281-20289.
    • Yao X, Chong H, Zhang C, Waltersperger S, Wang M, Cui S, He Y: Broad antiviral activity and crystal structure of HIV-1 fusion inhibitor sifuvirtide. J Biol Chem 2012, 287(9):6788-6796.
    • Zhang C, Yang Y, Zhou X, Yang Z, Liu X, Cao Z, Song H, He Y, Huang P: The NS1 protein of influenza A virus interacts with heat shock protein Hsp90 in human alveolar basal epithelial cells: implication for virus-induced apoptosis. Virol J 2011, 8:181.
    • Liu L, Xie J, Sun J, Han Y, Zhang C, Fan H, Liu Z, Qiu Z, He Y, Li T: Longitudinal profiles of immunoglobulin G antibodies against severe acute respiratory syndrome coronavirus components and neutralizing activities in recovered patients. Scand J Infect Dis 2011, 43(6-7):515-521.
    • Cao Z, Liu L, Du L, Zhang C, Jiang S, Li T, He Y: Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J 2010, 7:299.
    • Jia L, Xu Y, Zhang C, Wang Y, Chong H, Qiu S, Wang L, Zhong Y, Liu W, Sun Y, Qiao F, Tomlinson S, Song H, Zhou Y, He Y: A novel trifunctional IgG-like bispecific antibody to inhibit HIV-1 infection and enhance lysis of HIV by targeting activation of complement. Virol J 2010, 7:142.
    • Zhang C, Yang Y, Zhou X, Liu X, Song H, He Y, Huang P: Highly pathogenic avian influenza A virus H5N1 NS1 protein induces caspase-dependent apoptosis in human alveolar basal epithelial cells. Virol J 2010, 7:51.
    • He Y, Barker SJ, MacDonald AJ, Yu Y, Cao L, Li J, Parhar R, Heck S, Hartmann S, Golenbock DT, Jiang S, Libri NA, Semper AE, Rosenberg WM, Lustigman S: Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells. J Immunol 2009, 182(7):4005-4016.
    • He Y, Cheng J, Lu H, Li J, Hu J, Qi Z, Liu Z, Jiang S, Dai Q: Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A 2008, 105(42):16332-16337.
    • He Y, Liu S, Li J, Lu H, Qi Z, Liu Z, Debnath AK, Jiang S: Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J Virol 2008, 82(22):11129-11139.
    • Xiao W, Du L, Liang C, Guan J, Jiang S, Lustigman S, He Y, Zhou Y: Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines. Vaccine 2008, 26(39):5022-5029.
    • He Y, Cheng J, Li J, Qi Z, Lu H, Dong M, Jiang S, Dai Q: Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol 2008, 82(13):6349-6358.
    • He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, Lu H, Jing W, Jiang S, Zhang L: Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008, 283(17):11126-11134.
    • He Y, Liu S, Jing W, Lu H, Cai D, Chin DJ, Debnath AK, Kirchhoff F, Jiang S: Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem 2007, 282(35):25631-25639.
    • Du L, Zhao G, He Y, Guo Y, Zheng BJ, Jiang S, Zhou Y: Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 2007, 25(15):2832-2838.
    • He Y: Immunogenicity of SARS-CoV: the receptor-binding domain of S protein is a major target of neutralizing antibodies. Adv Exp Med Biol 2006, 581:539-542.
    • He Y, Li J, Heck S, Lustigman S, Jiang S: Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J Virol 2006, 80(12):5757-5767.
    • He Y, Li J, Du L, Yan X, Hu G, Zhou Y, Jiang S: Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine 2006, 24(26):5498-5508.
    • He Y, Li J, Li W, Lustigman S, Farzan M, Jiang S: Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006, 176(10):6085-6092.
    • He Y, Li J, Jiang S: A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem Biophys Res Commun 2006, 344(1):106-113.
    • He Y, Zhou Y, Siddiqui P, Niu J, Jiang S: Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J Clin Microbiol 2005, 43(8):3718-3726.
    • He Y, Jiang S: Vaccine design for severe acute respiratory syndrome coronavirus. Viral Immunol 2005, 18(2):327-332.
    • He Y, Lu H, Siddiqui P, Zhou Y, Jiang S: Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 2005, 174(8):4908-4915.
    • He Y, Zhu Q, Liu S, Zhou Y, Yang B, Li J, Jiang S: Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005, 334(1):74-82.
    • He Y, Zhou Y, Siddiqui P, Jiang S: Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry. Biochem Biophys Res Commun 2004, 325(2):445-452.
    • He Y, Zhou Y, Wu H, Kou Z, Liu S, Jiang S: Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus. J Clin Microbiol 2004, 42(11):5309-5314.
    • He Y, Zhou Y, Liu S, Kou Z, Li W, Farzan M, Jiang S: Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem Biophys Res Commun 2004, 324(2):773-781.
    • He Y, Zhou Y, Wu H, Luo B, Chen J, Li W, Jiang S: Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 2004, 173(6):4050-4057.
    • He Y, D'Agostino P, Pinter A: Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120-CD4 complex in transgenic mice that produce human immunoglobulins. Vaccine 2003, 21(27-30):4421-4429.
    • He Y, Honnen WJ, Krachmarov CP, Burkhart M, Kayman SC, Corvalan J, Pinter A: Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci. J Immunol 2002, 169(1):595-605.
    Copyright © 2012 Institute of Pathogen Biology, CAMS & PUMC